Patients Better Suited for GLP-1 Therapy Patients suffering from class III obesity who require profound, immediate weight loss for immediate health reasons are often better suited for GLP-1 therapies like semaglutide
Preclinical fat-loss evidence Ng et al
No published study has shown BPC-157 causes cancer in humans or animals, and some preclinical work even suggests anti-tumor activity in certain models, but the mechanism means caution is warranted rather than dismissed
However, high-dose niacin (as a medication for cholesterol) is generally not recommended during breastfeeding, because significant amounts could enter milk and cause unwanted effects in the nursing infant (flushing, for example)
Some research indicates semaglutide associates with laboratory results showing low b12 levels that do not reflect actual tissue deficiency
Estrogen and sulfur-containing hormones are kept at bay, and it helps defend harmful compounds in our system
&srotate=0)
